Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 10, 2017, Pages 2711-2716

  Lyke, Kirsten E ^a   Ishizuka, Andrew S ^b   Berry, Andrea A ^a   Chakravarty, Sumana ^c   DeZure, Adam ^b   Enama, Mary E ^b   James, Eric R ^c   Billingsley, Peter F ^c   Gunasekera, Anusha ^c   Manoj, Anita ^c   Li, Minglin ^c,d   Ruben, Adam J ^c   Li, Tao ^c   Eappen, Abraham G ^c   Stafford, Richard E ^c,d   Kc, Natasha ^c,d   Murshedkar, Tooba ^c   Mendoza, Floreliz H ^b   Gordon, Ingelise J ^b   Zephir, Kathryn L ^b   Holman, LaSonji A ^b   Plummer, Sarah H ^b   Hendel, Cynthia S ^b   Novik, Laura ^b   Costner, Pamela J M ^b   Saunders, Jamie G ^b   Berkowitz, Nina M ^b   Flynn, Barbara J ^b   Nason, Martha C ^b   Garver, Lindsay S ^e   Laurens, Matthew B ^a   Plowe, Christopher V ^a   Richie, Thomas L ^c   Graham, Barney S ^b   Roederer, Mario ^b   Kim Lee Sim, B ^c,d   Ledgerwood, Julie E ^b   Hoffman, Stephen L ^c   Seder, Robert A ^b   more..

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SANARIA INC   (United States)

^d Protein Potential LLC   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Live attenuated vaccine; Malaria; Plasmodium; Sporozoite; T cell immunology

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 2; MALARIA VACCINE; PLASMODIUM FALCIPARUM SPOROZOITE VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; LIVE VACCINE;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNIZATION; IN VITRO STUDY; MALARIA; MEMORY T LYMPHOCYTE; NONHUMAN; OPEN STUDY; PARASITEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; VACCINE IMMUNOGENICITY; ADOLESCENT; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALARIA FALCIPARUM; MALE; MIDDLE AGED; NORMAL HUMAN; PARASITOLOGY; PATHOGENICITY; PHASE 1 CLINICAL TRIAL; SPOROZOITE;

ADOLESCENT; ADULT; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; SPOROZOITES; T-LYMPHOCYTES; VACCINES, ATTENUATED;

EID: 85014696113     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1615324114     Document Type: Article

References (40)

1. Murray CJ, et al. (2012) Global malaria mortality between 1980 and 2010: A systematic analysis. Lancet 379(9814):413-431.
2. World Health Organization (2015) World Malaria Report 2015 (World Health Organization, Geneva).
3. Askling HH, Nilsson J, Tegnell A, Janzon R, Ekdahl K (2005) Malaria risk in travelers. Emerg Infect Dis 11(3):436-441.
4. Whitman TJ, et al. (2010) An outbreak of Plasmodium falciparum malaria in U.S. Marines deployed to Liberia. Am J Trop Med Hyg 83(2):258-265.
5. Hoffman SL, Vekemans J, Richie TL, Duffy PE (2015) The march toward malaria vaccines. Vaccine 33(Suppl 4):D13-D23.
6. Richie TL, et al. (2015) Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33(52):7452-7461.
7. Anonymous; RTS,S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet 386(9988):31-45.
8. Roestenberg M, et al. (2009) Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361(5):468-477.
9. Roestenberg M, et al. (2011) Long-term protection against malaria after experimental sporozoite inoculation: An open-label follow-up study. Lancet 377(9779):1770-1776.
10. Hoffman SL, et al. (2002) Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. JInfectDis185(8):1155-1164.
11. Seder RA, et al.; VRC 312 Study Team (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341(6152):1359-1365.
12. Egan JE, et al. (1993) Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49(2):166-173.
13. Schats R, et al. (2015) Heterologous protection against malaria after immunization with Plasmodium falciparum Sporozoites. PLoS One 10(5):e0124243.
14. Ishizuka AS, et al. (2016) Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22(6):614-623.
15. Preston MD, et al. (2014) A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains. Nat Commun 5:4052.
16. Walliker D, et al. (1987) Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 236(4809):1661-1666.
17. Stoute JA, et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336(2):86-91.
18. Kester KE, et al.; RTS,S Malaria Vaccine Evaluation Group (2001) Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183(4):640-647.
19. Kester KE, et al.; RTS,S Vaccine Evaluation Group (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection. JInfectDis200(3):337-346.
20. Ewer KJ, et al. (2013) Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4:2836.
21. Bijker EM, et al. (2013) Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 110(19):7862-7867.
22. Burkot TR, Williams JL, Schneider I (1984) Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg 78(3):339-341.
23. Schofield L, et al. (1987) Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330(6149):664-666.
24. Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF (1988) CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85(2):573-576.
25. Weiss WR, Jiang CG (2012) Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One 7(2):e31247.
26. Schwenk R, et al. (2013) Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigenspecific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vectored malaria vaccine expressing AMA1. Malar J 12:376.
27. Miller JD, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28(5):710-722.
28. Gros A, et al. (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22(4):433-438.
29. Epstein JE, et al. (2017) Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2(1):e89154.
30. Teirlinck AC, et al. (2011) Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog 7(12):e1002389.
31. Neafsey DE, et al. (2015) Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med 373(21):2025-2037.
32. Murphy SC, Kas A, Stone BC, Bevan MJ (2013) A T-cell response to a liver-stage Plasmodium antigen is not boosted by repeated sporozoite immunizations. Proc Natl Acad Sci USA 110(15):6055-6060.
33. Cockburn IA, Chakravarty S, Overstreet MG, García-Sastre A, Zavala F (2008) Memory CD8+ T cell responses expand when antigen presentation overcomes T cell self-regulation. J Immunol 180(1):64-71.
34. + T cell immunity. Science 334(6055):475-480.
35. Fernandez-Ruiz D, et al. (2016) Liver-resident memory CD8(+) T cells form a front-line defense against malaria liver-stage infection. Immunity 45(4):889-902.
36. Hoffman SL, et al. (2010) Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6(1):97-106.
37. 72. Federal Register 187 (2007), p 54917, Document Number E7-19155.
38. Chulay JD, et al. (1986) Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 35(1):66-68.
39. Rickman LS, et al. (1990) Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg 43(5):441-445.
40. Lyke KE, et al. (2010) Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: Results of a randomized infectivity trial. PLoS One 5(10):e13490.